Overview

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Status:
Not yet recruiting

Trial end date:
2025-05-13

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Temozolomide